Regulatory & compliance
Best Reasonable Efforts to end a global pandemic
01 March 2021 - Posted by: Marton Eorsi
Now that the COVID-19 vaccine contract between the EU and AstraZeneca has been published, we take a look at it and the “Best Reasonable Efforts” provisions. The production issues facing the roll-out of the EU vaccination programme have led some to question the centralised approach taken by the European Commission in its procurement of the › Read More
EU – Parallel trade in the life sciences sector – Q&A
24 February 2021 - Posted by: Francesca Miotto
On Tuesday, 26 January 2021, Allen&Overy (Belgium) LLP hosted a webinar on the key developments in parallel trade of pharmaceuticals in 2020. In this blog post, we discuss a few key topics and questions raised by the webinar’s participants. How will the competition law framework apply post-Brexit? Post-Brexit, companies active in the UK and the › Read More
22 February 2021 - Posted by: Alexis Vaujany
Given the growing number of digital tools that can be used in healthcare, the French National Authority for Health (HAS) has recently developed a system for classifying digital healthcare solutions according to their purpose of use, their capacity to provide a personalised response and their autonomy, i.e. their ability to act with or without human › Read More
Germany: CJEU referral on current practice in PI proceedings
27 January 2021 - Posted by: Birgit Kramer
With a decision of 19 January 2021, the Munich Regional Court (file number 21 O 16782/20) referred following question to the CJEU for a preliminary ruling: Is it compatible with Article 9 (1) of Directive 2004/48/EC that in proceedings for provisional measures the Higher Regional Courts with jurisdiction of the last instance generally refuse to › Read More
U.S. – Healthcare accent is on smaller deals
18 December 2020 - Posted by: Paul Burns
Transactions in the U.S. healthcare space rebounded in autumn, although with a greater proportion of smaller deals than in recent years. In the year to date, deal value has fallen sharply, but volume has decreased only marginally. Megadeals, common in the sector two or three years ago, are less frequent now. However, we did see › Read More